Origami Therapeutics
Biotechnology, Campus Pt Dr, San Diego, , 92121, California, 10210, United States, 1-10 Employees
Phone Number: 18*********
Who is ORIGAMI THERAPEUTICS
Origami Therapeutics is a preclinical-stage company developing novel protein degrader therapeutics with a proprietary drug discovery platform which holds the promise for disease-modificat...
Read More
-
Headquarters: 10210 Campus Pt Dr, San Diego, California, 92121, United States
-
Date Founded: 2016
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 1799
Does something look wrong? Fix it. | View contact records from ORIGAMI THERAPEUTICS
Origami Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Origami Therapeutics
Answer: Origami Therapeutics's headquarters are located at Campus Pt Dr, San Diego, , 92121, California, 10210, United States
Answer: Origami Therapeutics's phone number is 18*********
Answer: Origami Therapeutics's official website is https://origamitherapeutics.com
Answer: Origami Therapeutics's revenue is $1 Million to $5 Million
Answer: Origami Therapeutics's SIC: 1799
Answer: Origami Therapeutics has 1-10 employees
Answer: Origami Therapeutics is in Biotechnology
Answer: Origami Therapeutics contact info: Phone number: 18********* Website: https://origamitherapeutics.com
Answer: Origami Therapeutics is a preclinical-stage company developing novel protein degrader therapeutics with a proprietary drug discovery platform which holds the promise for disease-modification in neurodegenerative diseases such as Huntingtons Disease. We are pioneering the next-generation of small molecules targeting disease-causing proteins. At Origami Therapeutics, were leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a preclinical-stage biopharmaceutical company focused on developing new therapeutics for neurodegenerative diseases, beginning with Huntingtons Disease. Our proprietary protein degraders work by harnessing the bodys own natural protein disposal system to degrade and remove disease-causing proteins. We have built upon groundbreaking research of our founder Beth Hoffman, a veteran drug discovery scientist who discovered transformational therapeutics for cystic fibrosis. Origami is developing a broad technology platform focused on high-value targets, with the potential to deliver more potent therapies and to address the >80% of proteins that evade inhibition and have been undruggable by traditional approaches. Our lead programs are focused on neurodegenerative diseases, such as Alzheimers disease (AD), Parkinsons disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD) and Huntingtons disease (HD). Our hope is to unlock the full potential of ORIGAMI protein degradation by developing our own robust pipeline and by partnering with the worlds leading drug development companies.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month